The Experts below are selected from a list of 2451 Experts worldwide ranked by ideXlab platform
J.a. Hansen - One of the best experts on this subject based on the ideXlab platform.
-
Mixed Leukocyte Culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.
Bone marrow transplantation, 1992Co-Authors: G C Degast, Eric Mickelson, Patrick G. Beatty, Amos D, Keith M. Sullivan, H G Schoch, J.a. HansenAbstract:The results of pretransplant Mixed Leukocyte Culture (MLC) assays were compared to subsequent risk of graft-versus-host disease (GVHD) in 783 patients receiving marrow transplants from HLA genotypically identical sibling donors. The mean MLC response observed between 1303 normal HLA identical sibling pairs was 0.0 +/- 4.2% RR. The donor anti-recipient MLC reaction, an in vitro response that presumably might be relevant to GVHD, was significantly increased (greater than mean + 2 sd) in 83 (10.6%) of the cases, most often in patients in relapse at the time of testing. No association was found, however, between this increased donor anti-recipient MLC reactivity pretransplant and the incidence or severity of subsequent acute or chronic GVHD. These data suggest that the increased MLC responses sometimes observed between leukemia patients and their HLA identical sibling donors prior to marrow transplantation do not represent genetic differences capable of causing GVHD.
G C Degast - One of the best experts on this subject based on the ideXlab platform.
-
Mixed Leukocyte Culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.
Bone marrow transplantation, 1992Co-Authors: G C Degast, Eric Mickelson, Patrick G. Beatty, Amos D, Keith M. Sullivan, H G Schoch, J.a. HansenAbstract:The results of pretransplant Mixed Leukocyte Culture (MLC) assays were compared to subsequent risk of graft-versus-host disease (GVHD) in 783 patients receiving marrow transplants from HLA genotypically identical sibling donors. The mean MLC response observed between 1303 normal HLA identical sibling pairs was 0.0 +/- 4.2% RR. The donor anti-recipient MLC reaction, an in vitro response that presumably might be relevant to GVHD, was significantly increased (greater than mean + 2 sd) in 83 (10.6%) of the cases, most often in patients in relapse at the time of testing. No association was found, however, between this increased donor anti-recipient MLC reactivity pretransplant and the incidence or severity of subsequent acute or chronic GVHD. These data suggest that the increased MLC responses sometimes observed between leukemia patients and their HLA identical sibling donors prior to marrow transplantation do not represent genetic differences capable of causing GVHD.
Eric Mickelson - One of the best experts on this subject based on the ideXlab platform.
-
Mixed Leukocyte Culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.
Bone marrow transplantation, 1992Co-Authors: G C Degast, Eric Mickelson, Patrick G. Beatty, Amos D, Keith M. Sullivan, H G Schoch, J.a. HansenAbstract:The results of pretransplant Mixed Leukocyte Culture (MLC) assays were compared to subsequent risk of graft-versus-host disease (GVHD) in 783 patients receiving marrow transplants from HLA genotypically identical sibling donors. The mean MLC response observed between 1303 normal HLA identical sibling pairs was 0.0 +/- 4.2% RR. The donor anti-recipient MLC reaction, an in vitro response that presumably might be relevant to GVHD, was significantly increased (greater than mean + 2 sd) in 83 (10.6%) of the cases, most often in patients in relapse at the time of testing. No association was found, however, between this increased donor anti-recipient MLC reactivity pretransplant and the incidence or severity of subsequent acute or chronic GVHD. These data suggest that the increased MLC responses sometimes observed between leukemia patients and their HLA identical sibling donors prior to marrow transplantation do not represent genetic differences capable of causing GVHD.
Patrick G. Beatty - One of the best experts on this subject based on the ideXlab platform.
-
Mixed Leukocyte Culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.
Bone marrow transplantation, 1992Co-Authors: G C Degast, Eric Mickelson, Patrick G. Beatty, Amos D, Keith M. Sullivan, H G Schoch, J.a. HansenAbstract:The results of pretransplant Mixed Leukocyte Culture (MLC) assays were compared to subsequent risk of graft-versus-host disease (GVHD) in 783 patients receiving marrow transplants from HLA genotypically identical sibling donors. The mean MLC response observed between 1303 normal HLA identical sibling pairs was 0.0 +/- 4.2% RR. The donor anti-recipient MLC reaction, an in vitro response that presumably might be relevant to GVHD, was significantly increased (greater than mean + 2 sd) in 83 (10.6%) of the cases, most often in patients in relapse at the time of testing. No association was found, however, between this increased donor anti-recipient MLC reactivity pretransplant and the incidence or severity of subsequent acute or chronic GVHD. These data suggest that the increased MLC responses sometimes observed between leukemia patients and their HLA identical sibling donors prior to marrow transplantation do not represent genetic differences capable of causing GVHD.
Amos D - One of the best experts on this subject based on the ideXlab platform.
-
Mixed Leukocyte Culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukemia.
Bone marrow transplantation, 1992Co-Authors: G C Degast, Eric Mickelson, Patrick G. Beatty, Amos D, Keith M. Sullivan, H G Schoch, J.a. HansenAbstract:The results of pretransplant Mixed Leukocyte Culture (MLC) assays were compared to subsequent risk of graft-versus-host disease (GVHD) in 783 patients receiving marrow transplants from HLA genotypically identical sibling donors. The mean MLC response observed between 1303 normal HLA identical sibling pairs was 0.0 +/- 4.2% RR. The donor anti-recipient MLC reaction, an in vitro response that presumably might be relevant to GVHD, was significantly increased (greater than mean + 2 sd) in 83 (10.6%) of the cases, most often in patients in relapse at the time of testing. No association was found, however, between this increased donor anti-recipient MLC reactivity pretransplant and the incidence or severity of subsequent acute or chronic GVHD. These data suggest that the increased MLC responses sometimes observed between leukemia patients and their HLA identical sibling donors prior to marrow transplantation do not represent genetic differences capable of causing GVHD.